Waqar Khalid Saeed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Waqar Khalid Saeed has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Dae Won Jun
Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
18 shared publications Jai Sun Lee
Department of Translational Medicine, Hanyang University Graduate school of Biomedical Science and Engineering, Seoul, South Korea
7 shared publications- Hyeon Tae Kang
Department of Translational Medicine, Hanyang University Graduate school of Biomedical Science and Engineering, Seoul, South Korea
6 shared publications Yeon Ji Chae
Department of Translational Medicine, Hanyang University Graduate school of Biomedical Science and Engineering, Seoul, South Korea
5 shared publicationsKiseok Jang
Department of Pathology, Hanyang University School of Medicine, Seoul, South Korea
4 shared publications- Kiseok Jang
Department of Pathology, Hanyang University College of Medicine, Seoul 04763, Korea
4 shared publications
Latest Publications
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.
- 25 October 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (11) , e21979
BTT‐105 ameliorates hepatic fibrosis in non‐alcoholic fatty liver animal model
BTT‐105 (1‐O‐hexyl‐2,3,5‐trimethylhydroquinone), a hydroquinone derivative, is a potent anti‐oxidant that was safe and tolerable in phase I clinical trial. This study examined the anti‐fibrotic effect of BTT‐105 in a mouse model of non‐alcoholic fatty liver disease (NAFLD) along with the underlying mechanisms. In vivo, efficacy of BTT‐105 evaluated from three kinds of NAFLD models (methionine/choline deficient diet (MCD), high fat diet (HF) and western diet (WD)). Metabolomics and transcriptomics profiling analysis in liver tissues were conducted. In vitro, anti‐fibrotic effect of BTT‐105 assessed in human hepatic stellated cells (HSCs) and primary mouse HSCs. BTT‐105 improved NAFLD activity score in three kinds of NAFLD animal models (MCD, HF, and WD). BTT‐105 also decreased levels of hepatic pro‐collagen and collagen fibers deposition in liver tissue. Metabolome and transcriptome analysis revealed that BTT‐105 decreased lipid metabolites and increased antioxidants in NAFLD mice. In HepG2 cells, BTT‐105 enhanced Nrf2‐ARE reporter activity in a dose‐dependent manner and increased the levels of antioxidant gene expression. BTT‐105 showed inhibition of HSCs activation and migration. Gene expression profiling and protein expression showed that BTT‐105 increased Nrf2 activation as well as decreased PI3K‐Akt pathway in activated HSCs. BTT‐105 attenuated ameliorates steatohepatitis and hepatic fibrosis.
- 25 October 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (11) , e21979
BTT‐105 ameliorates hepatic fibrosis in non‐alcoholic fatty liver animal model
BTT‐105 (1‐O‐hexyl‐2,3,5‐trimethylhydroquinone), a hydroquinone derivative, is a potent anti‐oxidant that was safe and tolerable in phase I clinical trial. This study examined the anti‐fibrotic effect of BTT‐105 in a mouse model of non‐alcoholic fatty liver disease (NAFLD) along with the underlying mechanisms. In vivo, efficacy of BTT‐105 evaluated from three kinds of NAFLD models (methionine/choline deficient diet (MCD), high fat diet (HF) and western diet (WD)). Metabolomics and transcriptomics profiling analysis in liver tissues were conducted. In vitro, anti‐fibrotic effect of BTT‐105 assessed in human hepatic stellated cells (HSCs) and primary mouse HSCs. BTT‐105 improved NAFLD activity score in three kinds of NAFLD animal models (MCD, HF, and WD). BTT‐105 also decreased levels of hepatic pro‐collagen and collagen fibers deposition in liver tissue. Metabolome and transcriptome analysis revealed that BTT‐105 decreased lipid metabolites and increased antioxidants in NAFLD mice. In HepG2 cells, BTT‐105 enhanced Nrf2‐ARE reporter activity in a dose‐dependent manner and increased the levels of antioxidant gene expression. BTT‐105 showed inhibition of HSCs activation and migration. Gene expression profiling and protein expression showed that BTT‐105 increased Nrf2 activation as well as decreased PI3K‐Akt pathway in activated HSCs. BTT‐105 attenuated ameliorates steatohepatitis and hepatic fibrosis.
- 1 October 2019
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 8 (5) , 549-551
Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment
Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment
- 1 October 2019
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 8 (5) , 549-551
Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment
Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment
- 1 October 2019
- Published by Elsevier in Pharmacological Research
- Vol. 148, 104439
Necroptosis signaling in liver diseases: An update
- 1 October 2019
- Published by Elsevier in Pharmacological Research
- Vol. 148, 104439
Necroptosis signaling in liver diseases: An update
- 27 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (12) , 2206-2218
Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase
Background and Aim: Receptor‐interacting serine/threonine kinase 3 and mixed lineage kinase domain‐like pseudokinase (MLKL) have gained attention as apoptosis alternate cell death signaling molecules. We aimed to evaluate the role of MLKL in non‐alcoholic fatty liver disease (NAFLD).Methods: Hepatic tissue MLKL expression was compared between NAFLD patients and healthy controls. High‐fat diet was fed to wild‐type and MLKL‐knockout (KO) mice for 12 weeks. Brown adipose fat tissue was measured by [18F]‐fluorodeoxyglucose positron emission tomography. Energy expenditure was measured by indirect calorimetry. Anti‐MLKL effects were also evaluated in in vitro setting using U937 and HepG2 cells.Results: Hepatic tissue MLKL expression increased in NAFLD patients compared with healthy controls. MLKL expression increased according to the degree of steatosis, ballooning, and inflammation. High‐fat diet‐fed MLKL‐KO mice displayed decreased alanine aminotransferase, triglycerides, liver weight, NAFLD activity score (6.3 vs 3.5, P < 0.001), steatosis score (3.0 vs 1.8, P < 0.001), inflammation, and ballooning degeneration compared with wild‐type mice. SREBP1c, fatty acid synthase, and SCD‐1 expressions decreased in MLKL‐KO mice. Adipose tissue F4/80‐positive crown‐like structures were also reduced in MLKL‐KO mice. HepG2 cells treated with necrosulfonamide (an MLKL inhibitor) showed reduced Nile red staining and reduced SREBP1c and SCD‐1 expressions. Stimulation of necroptosis using lipopolysaccharide + caspase inhibitor (zVAD) increased CXCL1/2 expressions in U937 monocyte cells. Lipopolysaccharide + zVAD‐induced increased expressions of CXCL1/2 were reduced with necrosulfonamide treatment.Conclusions: Mixed lineage kinase domain‐like pseudokinase inhibition has protective effects in non‐alcoholic steatohepatitis by decreasing hepatic de novo fat synthesis and chemokine (C‐X‐C motif) ligand expressions.
- 27 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (12) , 2206-2218
Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase
Background and Aim: Receptor‐interacting serine/threonine kinase 3 and mixed lineage kinase domain‐like pseudokinase (MLKL) have gained attention as apoptosis alternate cell death signaling molecules. We aimed to evaluate the role of MLKL in non‐alcoholic fatty liver disease (NAFLD).Methods: Hepatic tissue MLKL expression was compared between NAFLD patients and healthy controls. High‐fat diet was fed to wild‐type and MLKL‐knockout (KO) mice for 12 weeks. Brown adipose fat tissue was measured by [18F]‐fluorodeoxyglucose positron emission tomography. Energy expenditure was measured by indirect calorimetry. Anti‐MLKL effects were also evaluated in in vitro setting using U937 and HepG2 cells.Results: Hepatic tissue MLKL expression increased in NAFLD patients compared with healthy controls. MLKL expression increased according to the degree of steatosis, ballooning, and inflammation. High‐fat diet‐fed MLKL‐KO mice displayed decreased alanine aminotransferase, triglycerides, liver weight, NAFLD activity score (6.3 vs 3.5, P < 0.001), steatosis score (3.0 vs 1.8, P < 0.001), inflammation, and ballooning degeneration compared with wild‐type mice. SREBP1c, fatty acid synthase, and SCD‐1 expressions decreased in MLKL‐KO mice. Adipose tissue F4/80‐positive crown‐like structures were also reduced in MLKL‐KO mice. HepG2 cells treated with necrosulfonamide (an MLKL inhibitor) showed reduced Nile red staining and reduced SREBP1c and SCD‐1 expressions. Stimulation of necroptosis using lipopolysaccharide + caspase inhibitor (zVAD) increased CXCL1/2 expressions in U937 monocyte cells. Lipopolysaccharide + zVAD‐induced increased expressions of CXCL1/2 were reduced with necrosulfonamide treatment.Conclusions: Mixed lineage kinase domain‐like pseudokinase inhibition has protective effects in non‐alcoholic steatohepatitis by decreasing hepatic de novo fat synthesis and chemokine (C‐X‐C motif) ligand expressions.
- Open Access
- 17 April 2019
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 13 (4) , 450-460
The Use of Foxa2-Overexpressing Adipose Tissue-Derived Stem Cells in a Scaffold System Attenuates Acute Liver Injury
Yeon Ji Chae, Dae Won Jun, Jai Sun Lee, Waqar Khalid Saeed, Hyeon Tae Kang, Kiseok Jang, and Jin Ho Lee. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18235
- 17 April 2019
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 13 (4) , 450-460
Open AccessThe Use of Foxa2-Overexpressing Adipose Tissue-Derived Stem Cells in a Scaffold System Attenuates Acute Liver Injury
Yeon Ji Chae, Dae Won Jun, Jai Sun Lee, Waqar Khalid Saeed, Hyeon Tae Kang, Kiseok Jang, and Jin Ho Lee. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18235
- Open Access
- 1 March 2019
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 34 (2) , 296-304
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis. The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], -0.30; 95% confidence interval [CI], -0.57 to -0.03) but not hepatic steatosis in RCT (SMD, -0.1; 95% CI, -0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, -3.0; 95% CI, -6.9 to 0.91). Ezetimibe decreased NAS without improving hepatic steatosis.
- 1 March 2019
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 34 (2) , 296-304
Open AccessEzetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis. The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], -0.30; 95% confidence interval [CI], -0.57 to -0.03) but not hepatic steatosis in RCT (SMD, -0.1; 95% CI, -0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, -3.0; 95% CI, -6.9 to 0.91). Ezetimibe decreased NAS without improving hepatic steatosis.
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Open AccessFeasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14
- Open Access
- 28 December 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (48) , 5477-5490
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease
- 28 December 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (48) , 5477-5490
Open AccessMismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease
- 12 November 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (3) , 781-791
Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold
Background Injecting MSCs via blood vessel is most commonly used method, which has a major drawback of safety. The aim of our study was to evaluate efficacy using scaffold-loaded MSCs in acute liver failure model. Method Acute liver failure was induced in mice using thioacetamide (TAA) (200 mg/kg, i.p) once a day for two consecutive days. The animals were divided in four acute liver failure groups: (1) TAA; (2) empty scaffold; (3) MSCs injected through tail vein; (4) MSC + Scaffold, scaffold loaded with MSCs, to evaluate the mortality and changes in liver function. Polylactic-co-glycolic acid scaffold alone and loaded with human MSCs was implanted on mice dorsum. Results TAA dose was titrated until one-third mortality rate was achieved. TAA (200 mg/kg) once daily for two consecutive days was injected to establish the acute liver failure model. The mortality of TAA and scaffold groups was 55.9% and 63.2%, respectively. Although, mortality of MSC-TV group decreased 14.7% as compared to TAA group (p = 0.200), MSC + Scaffold group had the lowest mortality (31.4%) (p = 0.013). Cells implanted in PLGA biomaterial were survived until 3 weeks, and their function was increased. Area of hepatic inflammation and necrosis was significantly reduced in MSC-TV and MSC + Scaffold groups; but there was no difference between the two groups. Gene expressions related to inflammation were significantly decreased in MSC-TV and MSC + Scaffold groups compared to TAA group. In MSC + Scaffold group, no migration of stem cells to liver tissue was observed. Although, not all cells in scaffold were stained, some of them were differentiated into hepatocyte-like cells which stained positive for PAS and CYP2E1 antibody. Conclusion Scaffold loaded with MSCs showed protective effects via paracrine signaling on acute liver failure model.
- 12 November 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (3) , 781-791
Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold
Background Injecting MSCs via blood vessel is most commonly used method, which has a major drawback of safety. The aim of our study was to evaluate efficacy using scaffold-loaded MSCs in acute liver failure model. Method Acute liver failure was induced in mice using thioacetamide (TAA) (200 mg/kg, i.p) once a day for two consecutive days. The animals were divided in four acute liver failure groups: (1) TAA; (2) empty scaffold; (3) MSCs injected through tail vein; (4) MSC + Scaffold, scaffold loaded with MSCs, to evaluate the mortality and changes in liver function. Polylactic-co-glycolic acid scaffold alone and loaded with human MSCs was implanted on mice dorsum. Results TAA dose was titrated until one-third mortality rate was achieved. TAA (200 mg/kg) once daily for two consecutive days was injected to establish the acute liver failure model. The mortality of TAA and scaffold groups was 55.9% and 63.2%, respectively. Although, mortality of MSC-TV group decreased 14.7% as compared to TAA group (p = 0.200), MSC + Scaffold group had the lowest mortality (31.4%) (p = 0.013). Cells implanted in PLGA biomaterial were survived until 3 weeks, and their function was increased. Area of hepatic inflammation and necrosis was significantly reduced in MSC-TV and MSC + Scaffold groups; but there was no difference between the two groups. Gene expressions related to inflammation were significantly decreased in MSC-TV and MSC + Scaffold groups compared to TAA group. In MSC + Scaffold group, no migration of stem cells to liver tissue was observed. Although, not all cells in scaffold were stained, some of them were differentiated into hepatocyte-like cells which stained positive for PAS and CYP2E1 antibody. Conclusion Scaffold loaded with MSCs showed protective effects via paracrine signaling on acute liver failure model.